Skip to main content
Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.070
-0.150 (-6.76%)
Nov 21, 2024, 11:49 AM EST - Market open

Fate Therapeutics Revenue

Fate Therapeutics had revenue of $3.07M in the quarter ending September 30, 2024, with 58.13% growth. This brings the company's revenue in the last twelve months to $13.45M, down -87.34% year-over-year. In the year 2023, Fate Therapeutics had annual revenue of $63.53M, down -34.03%.

Revenue (ttm)
$13.45M
Revenue Growth
-87.34%
P/S Ratio
17.98
Revenue / Employee
$74,293
Employees
181
Market Cap
235.76M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202363.53M-32.77M-34.03%
Dec 31, 202296.30M40.45M72.44%
Dec 31, 202155.85M24.41M77.66%
Dec 31, 202031.43M20.75M194.33%
Dec 31, 201910.68M5.94M125.32%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Zynex 193.67M
Anika Therapeutics 164.17M
Poseida Therapeutics 150.86M
NeuroPace 76.45M
Mersana Therapeutics 34.84M
Eton Pharmaceuticals 34.68M
Ocugen 4.70M
Artiva Biotherapeutics 2.60M
Revenue Rankings

FATE News

More News